In BRCA1‐proficient TNBC cells, we observed the same result—that elevated wild‐type KLF4 drastically promotes cancer cell survival in the presence of olaparib, whereas little effect was observed for expression of the PARylation‐deficient KLF4 mutant (Fig 7J–L). Here, BRCA1 is linked to cancer.